View Older Stories

Feb 28, 2014 06:37AM Needham & Company Downgrades Mylan (MYL) to Hold

Aug 2, 2013 10:40AM Notable Analyst Rating Changes 08/02: (MYL) (CTXS) (FLT) Upgraded; (MOS) (GME) (VCLK) Downgraded

Aug 2, 2013 08:44AM Needham & Company Downgrades Mylan (MYL) to Buy

May 3, 2013 12:21PM Mylan (MYL) Still a Strong Buy at Needham & Company

Sep 10, 2012 08:49AM Needham & Company Maintains a 'Buy' on Warner Chilcott (WCRX); Loses Appeal

Sep 10, 2012 08:43AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); Detrol LA Settlement Provides Small Dose of Certainty

Aug 24, 2012 08:05AM Needham & Company Maintains a 'Hold' on Par Pharmaceutical (PRX); Is Endo (ENDP) the 'Mystery Bidder'

Aug 24, 2012 07:59AM Needham & Company on Endo Pharmaceuticals (ENDP): Watson (WPI) Gains First Generic Lidoderm Approval; A Few Other Issues Too

Jul 27, 2012 10:51AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); Continuing to Grind Out Upside

Jul 20, 2012 08:31AM Needham & Company maintains a 'Strong Buy' on Mylan (MYL); PRX Grossly Undervalued by TGP, MYL/PRX Instead As Strong Combo

Jun 26, 2012 07:40AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); Brushing Off Generic Copaxone Loss

May 1, 2012 08:26AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); Chalk One Up in the PIV Win Column As Doryx Goes Generic

Feb 6, 2012 08:22AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL)l Mid-May Is D-Day for Generic Lidoderm, Not July

Dec 20, 2011 08:01AM Needham & Company: Specialty Pharmaceuticals - 2012 Preview: European Hangover Expected to Ease; Valuations Reflect Fear Not Fact

Oct 27, 2011 08:44AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); Dey After Dey EpiPen Continues to Deliver

Sep 7, 2011 08:38AM Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Whistleblower Lawsuit Accuses Par of Illegal Drug-Switching Scheme

Aug 26, 2011 07:30AM Teva (TEVA) May Be One of the Cheapest Pharmas Right Now - Barron's

Jul 28, 2011 09:04AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); U.S. Generic Dynamics Again Rule The Day As European Softness Persists

Jun 7, 2011 07:41AM Needham & Company Maintains a 'Hold' on Warner Chilcott (WCRX); Warning Letter Could Complicate “Sweetest” Doryx 150mg Settlement Outcomes

Jun 7, 2011 07:39AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); Likely Shared Exclusivity Slot Could Result in Upside Scenarios Following IPXL News

Feb 28, 2011 08:05AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); Generic Diovan HCT Exclusivity Suggests Dramatically Improved 2012-2013 EPS Visibility

Feb 25, 2011 08:39AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); U.S. Generic Fundamental Tailwinds Remain Strong; Current Euro Discount Affords Attractive Accumulation Opportunity

Dec 14, 2010 08:21AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); Less Can Be More; Valuation, Still Haunted By Ghost of Leverage Past

Jul 15, 2010 08:14AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); Bioniche Acquisition Doesn’t Cure European Hangover But Adds Solid Long-Term Growth Vehicle

Jul 13, 2010 07:29AM Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); Receives Final Approval for Generic Oracea Potentially Setting Up Exclusivity Launch

Jan 8, 2010 10:51AM Notable Analyst Rating Changes 1/8: HAL, AMAT, JCP, AGU, ESV, RDN, More Upgraded; M, KO, STX, ERIC, WEN, PCS, More Downgraded

Sep 25, 2008 07:55AM Needham & Co Initiates Coverage on Drugs - Generic

View Older Stories